glp 1 chronic kidney disease and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chronic kidney disease: doing simple

Managing GLP-1 side effects, preserving muscle, protecting your relationship with food and planning for life after the drug are all essential to long-term success

The SELECT trial evaluated patients with preexisting cardiovascular disease and overweight or obesity with semaglutide vs

I refused to believe that

[1] Unlike amphetamine abuse, where drug tolerance necessitates escalating doses to achieve the same effect, tolerance to clinically relevant doses of amphetamine plateaus after the initial titration period, and "drug holidays" (i.e., temporary treatment discontinuation) are not required to prevent the development of tolerance